Ocugen stock gained 1.96 percent before its October 6 panel

Published on 10/06/2026 at 11:49 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Ocugen stock carries a Moderate Buy consensus with a USD 9.50 average target as of October 3, 2026. Q2 revenue reached USD 1.49 million while EPS missed estimates.

OCGN, US67577C1053, Illustration mit AI erstellt.

Ocugen stock (ISIN US67577C1053) was last at USD 1.04 on Nasdaq on October 5, 2026, up 1.96 percent from the USD 1.02 prior close. The company entered October 6 with CEO Shankar Musunuri scheduled to discuss cell and gene therapy approval and commercialization at a Phoenix industry panel, according to StockTitan on September 29, 2026.

October 6 panel tests the story

The panel centers on the path from regulatory approval to commercialization, a relevant checkpoint for Ocugen as it advances modifier gene therapies for retinal diseases. The company is developing OCU400 for retinitis pigmentosa, OCU410 for geographic atrophy and OCU410ST for Stargardt disease.

The October 6 event follows a second-quarter update that linked a USD 130 million convertible-notes financing to a cash runway extending into 2028. Benzinga reported cash, cash equivalents and restricted cash of USD 100.4 million as of June 30, 2026.

Q2 loss widens as revenue grows

Ocugen generated USD 1.49 million in Q2 2026 revenue, compared with USD 1.37 million in Q2 2025, while its GAAP net loss widened to USD 24.88 million from USD 14.74 million. Those figures were reported by Markets Insider for the quarter ended June 30, 2026.

Diluted EPS was a USD 0.07 loss, versus a projected USD 0.05 loss, a USD 0.02 miss. Operating expenses reached USD 17.9 million in Q2 2026, up from USD 15.2 million a year earlier, according to Benzinga.

Analyst target remains far above the quote

MarketBeat reported on October 3, 2026, that five firms covering Ocugen assigned a Moderate Buy consensus, with four Buy ratings and one Sell rating. The average 12-month price target was USD 9.50, which lies 813.5 percent above the USD 1.04 Nasdaq quote.

The market value was USD 352.7 million on October 5, 2026, and the stock stood 7.2 percent above its 52-week low of USD 0.97. The gap between the modest revenue base and the multi-year clinical timetable leaves financing, trial execution and regulatory progress as the key variables behind the valuation.

Ocugen stock stays near its yearly low

Ocugen stock was last at USD 1.04 on Nasdaq on October 5, 2026, at 4:00 p.m. ET, with volume of 5,461,592 shares and a 52-week range of USD 0.97-2.73.